PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Firm”), a clinical-stage biotherapeutics firm devoted to discovering, growing and commercializing extremely differentiated medicines for devastating ailments, at present declares that Stephen Muniz, Esq., will retire from his function as Chief Working Officer and Company Secretary and can step down from the Board Of Administrators, efficient Could 17, 2021. Bharatt Chowrira, PhD, JD, PureTech’s President and Chief of Enterprise and Technique and a member of the Board, will assume the tasks beforehand held by Steve.
“On behalf of the Board, I wish to thank Steve for all of his onerous work and management over the previous 13 years,” mentioned Daphne Zohar, Founder and Chief Govt Officer of PureTech. “As a co-founder, Steve has been instrumental in serving to PureTech construct a world class operations and authorized group, leaving us well-positioned for the long run. We want him a lot continued success and all one of the best in his future endeavors.”
“It has been an honor to assist construct such an revolutionary firm,” mentioned Steve. “I’m wanting ahead to watching PureTech’s progress as they proceed to advance their necessary therapeutic candidates and ground-breaking discovery platforms for sufferers in want.”
PureTech’s Board of Administrators
PureTech’s Board of Administrators embrace former executives of main pharmaceutical firms, entrepreneurs, and award successful educational and medical leaders who leverage their experience to help our mission. The Board of Administrators is comprised of the next members:
Daphne Zohar, Founder, Chief Govt Officer and Director – Daphne Zohar is the Founder and Chief Govt Officer of PureTech, and he or she has served as a member of PureTech’s Board of Administrators for the reason that Firm’s founding. She has additionally served because the founding Chief Govt Officer of numerous PureTech’s Based Entities. A profitable entrepreneur, Ms. Zohar created PureTech, assembling a number one group to assist implement her imaginative and prescient for the Firm, and was a key participant in fundraising, enterprise growth and establishing the underlying packages and platforms which have resulted in PureTech’s substantial pipeline.
Chris Viehbacher, Board Chair – Chris Viehbacher has served as a member of PureTech’s Board of Administrators since 2015 and as Chair since September 2019. He’s the Managing Companion of Gurnet Level Capital, a Boston based mostly funding fund related to the Bertarelli household and has a $2 billion capital allocation. He’s the previous CEO and member of the Board of Administrators of Sanofi and was additionally the Chair of the Board of Genzyme in Boston.
Bharatt Chowrira, PhD, JD, President, Chief of Enterprise and Technique and Director – Bharatt Chowrira, PhD, JD, is the President and Chief of Enterprise and Technique of PureTech, and he has served as a member of PureTech’s Board of Director’s since 2021. Previous to becoming a member of PureTech, Dr. Chowrira was the President of Synlogic, Inc. He beforehand served because the Chief Working Officer of Auspex Prescription drugs Inc., till its acquisition by Teva Prescription drugs, and he has held numerous management and administration positions throughout the biopharmaceutical business.
Raju Kucherlapati, PhD, Unbiased Non-Govt Director – Raju Kucherlapati, PhD, has served as a member of PureTech’s Board of Administrators since 2014. He’s the Paul C. Cabot Professor of Genetics and Professor of Medication at Harvard Medical College. Dr. Kucherlapati was a founder and previously a board member of Abgenix (acquired by Amgen for $2.2 billion), Cell Genesys and Millennium Prescription drugs (acquired by Takeda for $8.8 billion).
John LaMattina, PhD, Unbiased Non-Govt Director – John LaMattina, PhD, has served as a member of PureTech’s Board of Administrators since 2009. Dr. LaMattina was beforehand president of Pfizer International Analysis and Growth and held positions of accelerating duty throughout his 30-year profession at Pfizer.
Bob Langer, ScD, Co-Founder and Non-Govt Director – Bob Langer, ScD, is a Co-founder of PureTech and has served as a member of PureTech’s Board of Administrators for the reason that Firm’s founding. He has served because the David H. Koch Institute Professor at MIT since 2005. He’s one in all 12 institute professors, which is the best honor that may be awarded to a school member at MIT. Dr. Langer has acquired over 220 main awards and is probably the most cited engineer in historical past.
Kiran Mazumdar-Shaw, Unbiased Non-Govt Director – Kiran Mazumdar-Shaw has served as a member of PureTech’s Board of Administrators since 2020. She is a pioneering biotech entrepreneur, a healthcare visionary, a worldwide influencer and a passionate philanthropist. She is a pioneer of India’s biotech business and founding father of Biocon.
Dame Marjorie Scardino, Senior Unbiased Director – Dame Marjorie Scardino has served as a member of PureTech’s Board of Administrators since 2015. She served as Chief Govt of The Economist for 12 years and was the Chief Govt of Pearson plc, the world’s main schooling firm and the proprietor of Penguin Books and The Monetary Occasions Group. She served as chairman of The MacArthur Basis from 2012 to 2017, and later grew to become the Chairman of the London College of Hygiene and Tropical Medication.
About PureTech Well being
PureTech is a clinical-stage biotherapeutics firm devoted to discovering, growing and commercializing extremely differentiated medicines for devastating ailments, together with intractable cancers, lymphatic and gastrointestinal ailments, central nervous system problems and inflammatory and immunological ailments, amongst others. The Firm has created a broad and deep pipeline by means of the experience of its skilled analysis and growth group and its in depth community of scientists, clinicians and business leaders. This pipeline, which is being superior each internally and thru PureTech’s Based Entities, as of the date of PureTech’s most lately filed Registration Assertion on Type 20-F, was comprised of 24 therapeutics and therapeutic candidates, together with two which have acquired FDA clearance and European advertising and marketing authorization. All the underlying packages and platforms that resulted on this pipeline of therapeutic candidates have been initially recognized or found after which superior by the PureTech group by means of key validation factors based mostly on the Firm’s distinctive insights into the biology of the mind, immune and intestine, or BIG, techniques and the interface between these techniques, known as the BIG Axis.
For extra data, go to www.puretechhealth.com or join with us on Twitter @puretechh.
Cautionary Notice Concerning Ahead-Trying Statements
This press launch comprises statements which are or could also be forward-looking statements, together with statements that relate to the corporate’s future prospects, developments, and techniques. The forward-looking statements are based mostly on present expectations and are topic to identified and unknown dangers and uncertainties that might trigger precise outcomes, efficiency and achievements to vary materially from present expectations, together with, however not restricted to, our expectations concerning the potential therapeutic advantages of our therapeutic candidates and people dangers and uncertainties described within the threat elements included within the regulatory filings for PureTech Well being plc. These forward-looking statements are based mostly on assumptions concerning the current and future enterprise methods of the corporate and the atmosphere wherein it’s going to function sooner or later. Every forward-looking assertion speaks solely as on the date of this press launch. Besides as required by legislation and regulatory necessities, neither the corporate nor another get together intends to replace or revise these forward-looking statements, whether or not on account of new data, future occasions or in any other case.
This announcement comprises inside data for the needs of Article 7 of Regulation (EU) 596/2014.
Allison Mead Talbot
+1 617 651 3156
+1 617 581 9333